01.23.26 -- Why The EU Biotech Act Matters To The U.S.: A Clinical Perspective

In clinical research, sponsor–vendor relationships are often framed as negotiations. Yet while both sides want to achieve a successful study, the process often becomes a tug-of-war.

Automating FDA data validation rules and analyzing audit trail data can significantly reduce fraud and predict areas of concern. Discover how these advancements can transform your clinical trials.

This expert panel explores how Australia, Taiwan, and South Korea provide a strategic advantage in conducting early, mid, and late-phase oncology trials.

Review new transparency requirements for NIH-funded institutions engaged in research involving r/sNA molecules and regulations for Institutional Biosafety Committees (IBCs).

When data is missing or delayed, it can slow down trial progress. Improving EHR data quality strengthens clinical research and ensures faster access to life-changing therapies for patients in need.

Through dedicated staffing, operational oversight, and collaboration with site teams, see how a struggling cardiology study transformed into a revitalized recruitment effort.

By aligning biometrics expertise with advanced technologies and global regulatory standards, sponsors can optimize resources, ensure patient safety, and bring transformative therapies to market faster.

With each batch of cell and gene therapy product representing a wealth of lifesaving potential, this biopharma company needed the right packaging solution for its relatively new therapy applications.